MedTrace Logo

Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

NCT02739828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2019-08-09

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. Participants will be treated in accordance with normal routine clinical care.

Conditions

Interventions

BIOLOGICAL

Adalimumab

Adalimumab

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-07
Primary Completion
2018-03-28
Completion
2018-03-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02739828 on ClinicalTrials.gov